The present Competitive Intelligence Report about Cancer Antibodies in Early
Clinical Development provides a competitor evaluation in the field of antibody
therapeutics being developed for treatment of solid and hematologic
malignancies as of February 2011. Purchase of the downloadable pdf report
includes a 6-month online access to the data of the report and any updates
since the publication date. Credentials to access the database will be sent by
e-mail and allow online work with the project data to print or export an
individual report.
Marketed therapeutic antibodies for treatment of cancer achieved combined
sales of over US$ 18 bln in the year 2009. Among them are the blockbuster
antibodies Avastin, Rituxan/MabThera and Herceptin. The development pipeline
of novel cancer antibodies in early clinical phases is full, not only of
antibodies against the validated targets CD20, VEGF and Her2, but also of many
new and unique antibodies directed against novel targets which will have to
show its clinical validity. The technology of antibody-drug conjugates is
gaining popularity as evidenced by an ever growing pipeline.
The report includes a compilation of currently active projects in early
clinical research and development of antibody therapeutic for treatment of
cancer. In addition, the report lists company-specific R&D pipelines of
anti-cancer antibodies. Competitor projects are listed in a tabular format
providing information on:
Drug Codes,
Target / Mechanism of Action,
Class of Compound,
Company,
Product Category,
Indication,
R&D Stage and
additional comments with a hyperlink leading to the source of information.
Corporate Early Clinical Stage Cancer Antibody R&D Pipelines
Abbott
Active Biotech
Affimed Therapeutics
Albert Einstein College of Medicine
Alder Biopharmaceuticals
Alexion Pharmaceuticals
Altor Biosciences
Amgen
Angimmune
Apeiron Biologics
Apogenix
Astellas Pharma
AstraZeneca
AVEO Pharmaceutical
Bayer Schering Pharma
Biocon
Biogen Idec
BioInvent
Biotest
BioWa
Boehringer Ingelheim Pharmaceuticals
Bristol-Myers Squibb (BMS)
BZL Biologics
Celldex Therapeutics
Celltrion
Centocor (J&J)
CureTech
Daiichi-Sankyo
Debiopharm
Dong-A Pharmaceutical
Eisai
Eli Lilly
Emergent Biosolutions
Fibrogen
Five Prime Therapeutics
Fresenius Biotech
Ganymed Pharmaceuticals
Genmab
Genzyme
GlaxoSmithKline
Glycotope
Helix BioPharma
Hokkaido UniversityHospira
Human Genome Sciences
ImaginAb
ImmunogenImmunomedics
Innate Pharma
Kissei Pharmaceutical
Kyowa Hakko Kirin Pharma
LFB Biotechnologies
Life Science Pharmaceuticals
Lpath
Ludwig Institute for Cancer Research (LICR)
MAbgen
MacroGenics
MAT Biopharma
MD Anderson Cancer Center
Memorial Sloan Kettering
Mentrik Biotech
Merck & Co
Merck Serono
Merrimack Pharmaceuticals
Micromet
MorphoSys
National Cancer Institute (NCI)
Neogenix Oncology
Novartis
Ono
OncoMed Pharmaceuticals
Oncoscience
Pain Therapeutics
PanGenetics
Patrys
Peregrine Pharmaceutical
Pfizer
Philogen
Progenics
Provenance Biopharmaceuticals
Quest PharmaTech
Radboud University
Recepta Biopharma
Regeneron Pharmaceuticals
Roche (Genentech)
Sanofi-Aventis
Seattle Genetics
Scott & White Hospital and Clinic
Simmons Cancer Center
Spectrum Pharmaceuticals
Symphogen
Takeda
Targa Therapeutics
TenX Biopharma
Teva Pharmaceutical Industries
ThromboGenics
TopoTarget
TRACON Pharmaceutical
TRION Pharma
United Therapeutics
UCB
Vaccinex
Viventia Biotech
Weill Medical College
Wilex
XBiotech
Xencor
XOMA
YM Biosciences
Zenotech
About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information
about the pipeline of R&D projects for targets, diseases, technologies and
companies at low prices. The information is provided in a tabular format and
fully referenced.
Table of Contents
Table of Contents
1. Cancer Antibodies in Early Clinical Development
Competitor Analysis: Cancer Antibodies in Early Clinical Development published by La Merie Publishing in February 1, 2011. This report consists of 183 Pages and the price starts from US $ 1210.
